The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today. The DSMB ...
(RTTNews) - Biotechnology company Ocugen, Inc. (OCGN) announced Monday that the independent Data and Safety Monitoring Board (DSMB) for its Phase 1/2 clinical trial of OCU400 recommended that the ...
BERWYN, PA.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback